DNA-PK-selective kinase inhibitor
oral efficacy in xenograft radiation models
undisclosed screening and optimization
Mol. Cancer Ther., Mar. 27, 2020
Merck KGaA, Darmstadt, DE
M3814
1 min read
M3814 (Merck KGaA oral DNA-PK selective kinase inhibitor)
Search By Structure
- CC-92480
- “PROTAC 6”
- GSK620
- Merck hArg1 inhibitor
- Merck IDO1 inhibitor
- Constellation EZH2 inhibitor
- Arcus CD73 inhibitor
- MK-6884
- Sulfopin
- M3814
- Remibrutinib
Molecules of the Month
2023
2022
2021
2020